Abstract
Background
Membranous nephropathy is a glomerular disease characterized by the presence of immune-complexes deposited in the subepithelial space of the glomerular basement membrane. It is the main cause of nephrotic syndrome in adults, while in children it is very infrequent. Anti-CD20 monoclonal antibodies, mainly rituximab, represent a specific treatment for this disease.
Case report
We report the case of a child presenting at 2 years of age with steroid-resistant nephrotic syndrome diagnosed upon kidney biopsy as semaphorin 3B (SEMA3B)-associated primary membranous nephropathy. The patient responded to treatment with cyclosporine, but invariably relapsed upon tapering of this agent. Therefore, at age 9, he was successfully treated with rituximab to overcome cyclosporine dependence. However, after the second rituximab infusion, a rapid reconstitution of CD19 + B cells and a relapse of proteinuria occurred, requiring reintroduction of cyclosporine. Obinutuzumab, a type II anti-CD20 monoclonal antibody, was then infused inducing prolonged CD19 + B cell depletion and remission of proteinuria despite discontinuation of cyclosporine. A greater reduction in circulating anti-SEMA3B antibodies assessed by Western blot was observed after obinutuzumab compared with rituximab infusion.
Discussion
Obinutuzumab was safe and well-tolerated, and may therefore represent an effective therapeutic alternative in children with primary MN and rituximab resistance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ronco P, Beck L, Debiec H et al (2021) Membranous nephropathy. Nat Rev Dis Primers 7:69
Sethi S, Debiec H, Madden B et al (2020) Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int 98:1253–1264
Fila M, Debiec H, Perrochia H et al (2022) Recurrence of Anti-Semaphorin 3B-Mediated membranous nephropathy after kidney transplantation. J Am Soc Nephrol 33:503–509
Gauckler P, Shin JI, Alberici F et al (2021) Rituximab in membranous nephropathy. Kidney Int Rep 6:881–893
Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int 100:753–779
Reddy V, Klein C, Isenberg DA et al (2017) Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology 56:1227–1237
Sethi S, Kumar S, Lim K, Jordan SC (2020) Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy. Kidney Int Rep 5:1515–1518
Acknowledgements
The authors wish to thank the patient and his family, and all medical and nursing staff involved in his care.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Ester Conversano and Hanna Debiec contributed equally and should be considered joint first authors.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Conversano, E., Debiec, H., Colucci, M. et al. A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance. Pediatr Nephrol 39, 305–308 (2024). https://doi.org/10.1007/s00467-023-06085-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-023-06085-8